Ticagrelor Tablet
Product Images NDC 73190-003

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 73190-003). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (003 60)

The packaging label for Ticagrelor tablets by AvKARE shows the 60 mg strength. The label includes the NDC 73190-003-60 and indicates the package contains 60 tablets. It features usage warnings, storage instructions, and manufacturing information by AvKARE and MSN Pharmaceuticals Inc. A barcode is also visible on the right side.*

FDA Label Image

Tica-tabs-fig-01 (Tica Tabs Fig 01)

A cumulative incidence curve graph comparing event rates over 360 days for patients taking Ticagrelor 90 mg versus Clopidogrel. The x-axis represents days from first study drug dose, and the y-axis shows cumulative percentage. A small inset table lists patient counts and events for each treatment group at 12 months.*

FDA Label Image

Tica-tabs-fig-02 (Tica Tabs Fig 02)

A bar chart comparing the percentage of patients who had an event following CABG surgery over time in days. It displays paired bars labeled T and C for each time point (1, 2, 3, 4, 5, 7, and >=8 days), showing event percentages for two groups identified by T and C with specific sample sizes noted below each pair.*

FDA Label Image

Tica-tabs-fig-03 (Tica Tabs Fig 03)

A cumulative percentage line graph comparing two groups, labeled Ticagrelor and Placebo, over a timeline of 0 to 54 months from randomization. The y-axis represents cumulative percentage, showing higher values for Ticagrelor across the study duration, with a legend indicating event counts for each group.*

FDA Label Image

Tica-tabs-fig-04 (Tica Tabs Fig 04)

A Kaplan-Meier curve graph depicting cumulative event rates for Ticagrelor 60 mg tablet versus placebo over 34 days from randomization. The x-axis represents days from randomization; the y-axis shows cumulative event rate. The graph compares the two groups' event occurrence over time.*

FDA Label Image

Tica-tabs-fig-05 (Tica Tabs Fig 05)

A line graph comparing the percentage of platelet aggregation inhibited by Ticagrelor 180 mg, Clopidogrel 600 mg, and Placebo over time in hours. The y-axis represents platelet aggregation inhibition percentage, and the x-axis shows time from 0 to 8 hours.*

FDA Label Image

Tica-tabs-fig-06 (Tica Tabs Fig 06)

A graph showing platelet aggregation inhibition (IPA %) over time (days) for Ticagrelor, Clopidogrel, and Placebo. The inset graph displays IPA inhibition by 20 µM ADP over hours up to 48. Lines represent data points for each treatment group, demonstrating different inhibition profiles across the time intervals.*

FDA Label Image

Tica-tabs-fig-07 (Tica Tabs Fig 07)

A forest plot chart comparing the mean effect and 90% confidence interval of Ticagrelor for various intrinsic factors including age, gender, ethnicity, renal impairment, end stage renal disease on hemodialysis, and mild hepatic impairment versus normal conditions. The chart depicts changes relative to reference for pharmacokinetic parameters Cmax and AUC, with recommendations of no dose adjustment across all factors.*

FDA Label Image

Tica-tabs-fig-08 (Tica Tabs Fig 08)

A clinical interaction chart showing mean effects and 90% confidence intervals of various interacting drugs on Ticagrelor and AR-C124910XX, with recommendations listed. Interacting drugs include CYP3A4 inhibitors and inducers, aspirin, desmopressin, heparin, enoxaparin, cyclosporine, morphine, and fentanyl. The graph plots change relative to reference for PK parameters Cmax and AUC, with recommendations for dose adjustments or concomitant use.*

FDA Label Image

Tica-tabs-fig-09 (Tica Tabs Fig 09)

A chart displaying the mean effect and 90% confidence intervals for various drug interactions with ticagrelor at specified doses. The horizontal axis measures change relative to the interacting drug alone, with data points for Cmax and AUC shown for each drug. Recommendations on dose adjustments accompany each drug, mostly indicating no dose adjustment except for simvastatin, where a maximum dose is noted.*

FDA Label Image

Tica-tabs-fig-10 (Tica Tabs Fig 10)

A cumulative percentage line graph comparing two groups labeled Ti 90 mg and Clopidogrel over 360 days from randomization. The x-axis represents days from randomization, and the y-axis shows cumulative percent values. The graph includes a legend box showing event numbers, percentages, and statistical data for both groups.*

FDA Label Image

Tica-tabs-fig-11 (Tica Tabs Fig 11)

A forest plot comparing the hazard ratios (HR) with 95% confidence intervals (CI) of Ticagrelor versus Clopidogrel across various clinical characteristics and subgroups, including geographic region, treatment approach, diabetes history, age, sex, and race. The plot displays HR values and confidence intervals in a horizontal bar format, illustrating comparative treatment effects in percentages per year.*

FDA Label Image

Tica-tabs-fig-12 (Tica Tabs Fig 12)

A forest plot chart displaying hazard ratios (HR) with 95% confidence intervals comparing Ticagrelor and Clopidogrel effectiveness across US and Non-US regions and varying ASA doses. The horizontal axis is logarithmic, ranging from 0.125 to 8, indicating whether Ticagrelor or Clopidogrel is favored by the data.*

FDA Label Image

Tica-tabs-fig-13 (Tica Tabs Fig 13)

A Kaplan-Meier cumulative incidence curve displaying event rates over days from randomization for Ticagrelor 90 mg, Ticagrelor 60 mg, and placebo groups. The graph includes hazard ratios with 95% confidence intervals and p-values comparing event occurrences between groups, illustrating patient outcomes during the study period.*

FDA Label Image

Tica-tabs-fig-14 (Tica Tabs Fig 14)

A forest plot chart comparing Ticagrelor versus Placebo across various characteristics such as age groups, sex, race, weight, BMI, history of myocardial infarction, time from qualifying MI to randomization, type of qualifying MI, stent use, prior treatments, and other factors. The chart displays hazard ratios (HR) with 95% confidence intervals (CI) and the number of events per number of participants per year for Ticagrelor and Placebo, illustrating the overall treatment effect and subgroup analyses.*

FDA Label Image

Tica-tabs-fig-15 (Tica Tabs Fig 15)

A line graph comparing cumulative percentage events over 54 months from randomization between Ticagrelor and Placebo groups. The graph features a solid line for Ticagrelor and a dashed line for Placebo, with event counts and risk numbers displayed below and a legend in the upper left corner. The y-axis shows cumulative percentage (%) and the x-axis shows months from randomization.*

FDA Label Image

Tica-tabs-fig-16 (Tica Tabs Fig 16)

A forest plot chart comparing hazard ratios (HR) with 95% confidence intervals for Ticagrelor versus placebo across various patient characteristics including age, sex, race, body mass index, history of diabetes or angina, and other clinical factors. Each subgroup is displayed with a point estimate and confidence interval, showing the relative risk between Ticagrelor and placebo groups.*

FDA Label Image

Tica-tabs-fig-17 (Tica Tabs Fig 17)

A Kaplan-Meier plot depicting cumulative percentage curves over time in days post-randomization for two groups: patients taking Ticagrelor 90 mg twice daily and patients on placebo. The chart compares the cumulative incidence of a measured outcome between the two groups from day 0 to approximately day 34.*

FDA Label Image

Tica-tabs-fig-18 (Tica Tabs Fig 18)

A forest plot chart displaying the hazard ratios (HR) with 95% confidence intervals for various patient characteristics comparing Ticagrelor versus placebo. The characteristics include age groups, sex, race, weight, BMI, geographic regions, diagnosis of index event, time to randomization and loading dose, diabetes, hypertension, prior ischemic events, ASA and statin use, and smoking status. The plot visually contrasts Ticagrelor and placebo event rates and their comparative effectiveness across subgroups.*

FDA Label Image

Tica-tabs-structure (Tica Tabs Structure)

Chemical structure of the active ingredient Ticagrelor, showing its molecular framework with characteristic rings and functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.